MedTrace Logo

Long-term Prognosis of Patients With Sepsis After Immunotherapy

NCT04901104 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 900

Last updated 2021-05-25

No results posted yet for this study

Summary

Current clinical studies of thymosin α1 for sepsis have focused on short-term outcomes (28-day or 90-day mortality), and lack of clinical data on long-term outcomes (3 year mortality) of patients with sepsis after immunotherapy.

Based on the preliminary clinical study (NCT02867267), this study will conduct long-term follow-up for sepsis patients to provide data support for the long-term prognosis of immunotherapy.

Conditions

  • Long-term Effects of Thymosin Alpha 1 Treatment

Interventions

DRUG

Thymosin Alpha1

Drug interventions have been done in previous clinical studies

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-01
Primary Completion
2026-12-31
Completion
2027-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04901104 on ClinicalTrials.gov